Clinical Trial

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2023-06-16; most recent amendment 2026-05-24.
Status change: Not Yet Recruiting → Recruiting 2023-09-05
Trial Details
NCT Number NCT05910827
Lead Sponsor Hummingbird Bioscience
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Nasopharyngeal Cancinoma (NPC), Squamous Cell Carcinoma
Enrollment 398 participants
Start Date 2024-02-05
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27